ecancer

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

6 Apr 2023

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

6 Apr 2023

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

6 Apr 2023

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

5 Apr 2023

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

5 Apr 2023

Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC

Dr Alberto Servetto - University of Naples Federico II, Naples, Italy

5 Apr 2023

Intraoperative radiotherapy treatment in the Philippines

Dr Henri Cartier Co - Philippine General Hospital, Manila, Philippines

4 Apr 2023

PSMO and the future of cancer care in the Philippines

Dr Rosario Pitargue - Philippine Society of Medical Oncology, Manila, Philippines

4 Apr 2023

Low value practices that result in poor patient outcomes in LMICs

Dr Arnold John Uson - Perpetual Succour Hospital of Cebu, Cebu, Philippines

4 Apr 2023

Key methods for handling difficult conversations in cancer care

Dr Madelaine Amurao-Amante - Philippine Society of Medical Oncology, Manila, Philippines

4 Apr 2023

Radiotherapy for multiple cancer types in the Philippines

Dr Michael Mejia - University of Santo Tomas Hospital, Manila, Philippines

4 Apr 2023

Tumour markers and their role in cancer treatment

Dr Jasper Andal - St Luke's Medical Center, Manila, Philippines

4 Apr 2023

More from ecancer